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Abstract
Background: Many serious diseases have a genetic basis which, from an evolutionary point of view, should have
been selected against, resulting in very low frequencies. The remarkable sustained prevalence of a number of
disease-associated alleles is therefore surprising. We believe that antagonistic pleiotropy, when multiple effects of a
gene have opposing effects on fitness (e.g., sickle cell disease), may be more widespread than typically considered.
We hypothesize that, rather than being an exception to the rule of genetic disorders, antagonistic pleiotropy may
be common.
Methods: We surveyed the medical literature in order to determine whether sufficient evidence exists to reassess
the nature of antagonistic pleiotropy; from being considered an unusual scenario to one that is anticipated. We
also used a simple population genetic model to examine the feasibility of antagonistic pleiotropy to act as a
mechanism to maintain polymorphism for serious genetic disorders even if the benefits are subtle.
Results: We identified a number of examples of antagonistic pleiotropy where the deleterious effect, the beneficial
effect, and the exact molecular cause have been demonstrated. We also identified putative cases in which there is
circumstantial evidence or a strong reason to expect antagonistic pleiotropy in a genetic disorder. The population
genetic model demonstrates that alleles with severe deleterious health effects can be maintained at medically
relevant frequencies with only minor beneficial pleiotropic effects.
Conclusion: We believe that our identification of several cases of antagonistic pleiotropy, despite the lack of
research on this question and the varied natures of the types of these disorders, speaks to both the
underappreciated nature of this phenomenon and its potentially fundamental importance. If antagonistic
pleiotropy is as common as our research suggests, this may explain why so many serious diseases, even apparently
environmentally caused ones, have a genetic component. Furthermore, acceptance of a genome full of
antagonistically pleiotropic genetic interactions poses important implications for clinical treatment and disease
prevention research, especially genetically based therapies.
Background
The human genome is the product of an evolutionary
history that combines mutational processes and natural
selection; since this process appears to be a very effec-
tive mechanism for optimizing many traits (i.e., adapta-
tion) it is reasonable to question why so many genetic
disorders (i.e., non-optimal alleles) exist. Genetic disor-
ders are typically defined as «mutant» alleles that confer
deleterious effects on their possessors (usually, but not
always, homozygotes for the mutant allele) relative to
those possessing wildtype or normal alleles. Although
genetic drift and mutation selection balance can explain
the presence of segregating allelic variation for deleter-
ious traits, many genetic disorders are present at fre-
quencies higher than we would expect from a historical
process by which mutations arise and are then elimi-
nated by selection over time. A potential resolution to
the discrepancy between our expectations of very low
rates of genetic disorders and our observations of
remarkably common genetic disorders involves
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aside from just the deleterious ones.
In contrast to long-held notions whereby single genes
encoded single functions (e.g., «the» eye color gene),
most genes are now recognized to have multiple qualita-
tively distinct functions, a phenomenon termed pleio-
tropy [1]. A simple thought experiment where we
consider that the human genome has approximately
23,000 genes (with multiple genes involved in the for-
mation of each aspect of our phenotype) encoding a
phenotype with more than 23,000 aspects demonstrates
that many genes must have multiple functions. This
being the case, allelic variants that arise due to mutation
m a yc h a n g et h ep e r f o r m a n c e so ft h a tg e n e ’sf u n c t i o n s
differently such that sometimes these changes result in
opposing effects on fitness - i.e., some mutations can
improve the performance of one aspect of a gene’s func-
tion while simultaneously making another worse. Such a
phenomenon is termed antagonistic pleiotropy, the
pleiotropic functions of the same gene act antagonisti-
cally in terms of the fitness of the possessor. To date,
consideration of the implications of such antagonistically
pleiotropic effects has largely been the purview of stu-
dies of senescence.
Senescence is associated with distinct changes in the
physiology of individuals as they age [2]. Natural selec-
tion acts on differences in relative fitness (which is com-
prised of both mortality and reproduction) in
individuals within populations; the lack of natural selec-
tion to completely eliminate many deleterious senes-
cence-associated traits explains their sustained
prevalence in populations of humans. The most widely
held evolutionary explanation for the continued pre-
sence of senescence incorporates the aforementioned
antagonistic pleiotropy; an allele that causes deleterious
traits can actually be selected to increase in frequency
over time if the deleterious effects on the fitness of the
possessor are outweighed by other advantageous effects
also due to the allele [3].
Natural selection acts the strongest on traits mani-
fested during an organism’s peak reproductive value, an
age that corresponds to the beginning of reproduction
in most species (i.e., sexually mature, but young), and
benefits to an organism during this time increase overall
fitness more than those manifested at other ages [1]. In
contrast, natural selection is the weakest on traits mani-
fested after the majority of an organism’s reproduction
is complete (i.e., middle-aged or elderly), and detriments
to an organism during this time reduce overall fitness
less than those manifested at earlier ages. Pleiotropically
antagonistic alleles that provide a net increase in fitness
therefore tend to be those with benefits expressed at a
young age, favoring either fertility or survival, while the
detrimental phenotypes are not expressed or do not
display high penetrance until post-reproduction. A long
history of selection for, and fixation of, such antagonisti-
cally pleiotropic alleles is thought to account for bio-
chemical pathways and physiological processes that
work well in youth, but less well in older age - i.e.,
senescence [1,3].
Previous studies have discussed the influence of senes-
cence on different human diseases such as atherosclerosis
[4], sarcopenia [5], osteoporosis [6], immunodeficiency
disorders [7] and neurodegenerative disorders such as
Alzheimer’s([8] (see also a review in [9]). In fact, a num-
ber of alleles associated withar a n g eo fo t h e rd i s e a s e s
may have possessed similar antagonistically pleiotropic
effects and led to specific aspects of our senescence. For
example, it has been argued that positive selection and
sexual conflict may account for increased carcinoma risk
[10]. They reason that higher selective pressures due to
sexual and generational conflict resulted in positive selec-
tion, as suggested by relatively high rates of nucleotide
and amino acid sequence evolution in genes associated
with such conflicts, and that these changes had maladap-
tive pleiotropic side-effects that increase the rate of carci-
noma [10]. We suggest that in addition to antagonistic
pleiotropy contributing to the fixation of carcinoma caus-
ing mutations it may contribute similarly to current poly-
morphisms of other alleles associated with cancer and
other non-cancerous conditions.
Previous consideration of this topic has tended to
focus on selection that resulted in the fixation of alleles
that cause their deleterious effects in older age, changing
the default (i.e., wildtype) condition in the population. In
actuality, natural selection is often a slow and gradual
process and many alleles that differ in their effect on fit-
ness can be present in populations for prolonged peri-
ods, especially if the overall fitness differences are small.
For example, an allele that confers a noticeable disad-
vantage at one stage of life may also favor the individual
at another stage of life and if the net effect is small then
selection to change the allele’s frequency will be weak
and the frequency will be changed slowly by selection.
Natural selection can also act to actively maintain alleles
with individually deleterious effects in populations if
they act synergistically to increase fitness when present
together (e.g., via heterosis or epistatic interactions).
A clear example of a medically relevant antagonisti-
cally pleiotropic polymorphic allele was recently
described [11]. They conducted a cohort study of 99
individuals in Ecuador with Laron Syndrome, a rare
form of Dwarfism. Individuals with Laron Syndrome
may possess one of three different genotypes relating to
their Growth Hormone Receptor gene (GHR); most
individuals carry an A to G splice site mutation in posi-
tion 180 in exon 6 while some carry a nonsense muta-
tion designated as R43X and others are heterozygous for
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drome patients and their non-dwarf kin from 1988 to
1998 and recorded medical information. The study
found that patients with Laron Dwarfism experienced
virtually no incidences of cancer whereas their non-
Dwarf kin experienced a 17% cancer mortality rate.
Laron dwarfs also seemed to be protected from diabetes;
no incidences were reported among Laron patients
whereas their kin suffered a 5% mortality rate. The pre-
sence of the various mutant GHR alleles in this popula-
tion may be due to drift (the population is quite small
and relatively isolated), but may also be due to selection
acting to maintain this allele in the population due to
the benefits provided. While the allele described in this
case is rare and represents a minor overall effect on
health and fitness of the wider population, if this general
phenomenon of antagonistic pleiotropy is more com-
mon it may account for disorders that have more wide-
spread impact. The recognition that alleles identified as
being deleterious may also provide benefits is one that
we believe has been underappreciated in the medical
literature.
The purpose of this investigation is to determine
whether evidence of balancing selection due to antago-
nistic pleiotropy, heterosis or epistatic interactions is
seen in alleles associated with increased risk of certain
human diseases. As the phenomena of heterosis and
beneficial epistatic interactions are likely to arise from
the multi-functional nature of genes, we use the term
antagonistic pleiotropy as a catch-all term to refer to
alleles that act in any of these manners. If the net rela-
tive fitness conferred by pleiotropically antagonistic
alleles with mixed effects is higher, or even just compar-
able, to wildtype individuals then such alleles would
likely continue to persist in the population. If mutations
that create such pleiotropic alleles are not extremely
rare, widespread antagonistic pleiotropy may explain the
maintenance and high prevalence of many disease-asso-
ciated alleles. It becomes of great importance therefore
to determine whether antagonistically pleiotropic alleles
are likely to be rare or may be more common than pre-
viously realized.
Methods
In the body of this manuscript, evidence of antagonistic
pleiotropy in several major diseases is presented on a
disease by disease basis. The pleiotropic alleles, their
benefits and their pathophysiological costs are all briefly
outlined. Our review of the research literature supports
the hypothesis that at least some of the genetic factors
that increase disease severity or risk may also confer
certain reproductive or survival benefits, and therefore
provides support for the importance of antagonistic
pleiotropy as a causal mechanism for the persistence of
disease causing alleles. We would also like to stress that,
due to the lack of attention paid to the potential benefits
of alleles associated with different pathologies, we
believe that our collection of examples may only touch
the surface of the phenomenon and is a conservative
estimate of its prevalence. After describing a number of
conditions in detail (summarized in Tables 1 and 2) we
discuss possible implications of widespread antagonistic
pleiotropy for current and proposed medical treatments,
clinical trials and research.
Results
Huntington’s disease and Increased Fecundity
Huntington’s disease (HD) is a rare, autosomal domi-
nant neurodegenerative disorder in which symptoms
typically manifest at an age that is post-reproductive, in
the range of 30-45 years of age [12]. Affected individuals
often experience chorea, uncontrolled and involuntary
movements, in addition to a much shorter life-expec-
tancy. Onset of Huntington’s disease is attributed to the
presence of a high number of CAG trinucleotide repeat
lengths within the Huntingtin (HTT) gene [12,13]; in
particular, when the number of CAG repeats exceeds
37, onset of Huntington’s disease symptoms was much
more likely to occur [14].
Huntington’s patients show a notable increase in
fecundity when compared to the unaffected individuals
however, and may also experience lower rates of can-
cer. In a study of the relative fitness of affected and
unaffected individuals in Canada via a comparison of
the fitness values of 157 Huntington’s patients with
170 related wild-type individuals, the mean number of
offspring for the patients was 39% higher than their
unaffected siblings and 18% higher than a set of unre-
lated control individuals matched for age and sex [15].
That investigation went on to predict that if such fit-
ness values as he observed were genuine and were to
persist, the disease-associate polymorphisms may dou-
ble in frequency in as short as 150 years (roughly six
generations)[15].
An additional benefit that may be conferred by these
antagonistically pleiotropic polymorphisms is a reduced
risk of cancer [16]. Sorenson et al [17] reported that a
higher number of CAG repeats within the HTT allele is
associated with increased p53 activity. P53 is a tumor
suppressor protein that has a role in inducing apoptosis
and although apoptosis of neuronal cells may be the
major cause of the neuro-degeneration seen in Hunting-
ton’s patients, a higher level of p53 may also protect
from tumor growth and cancer development in general.
The increased CAG repeat length of HD individuals
may therefore be an explanation for the reduced inci-
dence of cancer seen in a large registry of Huntington’s
patients [17].
Carter and Nguyen BMC Medical Genetics 2011, 12:160
http://www.biomedcentral.com/1471-2350/12/160
Page 3 of 13Variation in the CAG repeat length within the HTT
gene therefore seems to exhibit a form of antagonistic
pleiotropy that perfectly illustrates that proposed by [3].
Presence of more than 37 CAG trinucleotide repeats in
the HTT gene is associated with an increased risk for
Huntington’s disease, but is also associated with a sub-
stantial rise in fertility and perhaps reduced cancer risk.
Cystic fibrosis and fertility
Cystic fibrosis (CF) is an autosomal recessive trait that is
often lethal, though life expectancy has increased over
time from early infancy to late-30s due to better medi-
cation, therapies and more access to medical care [18].
The mutation that causes CF is a codon deletion in the
CFTR gene that results in the loss of phenylalanine
from the protein product [19]. Loss of phenylalanine
results in a non-functional trans-membrane chloride
channel, a channel responsible for the movement of
bodily fluids throughout many different organs and
organ systems in the body. The presence of this
defective channel in the body leads to diverse symptoms
involving many organ systems and tissues, mainly due
to the buildup of fluids throughout the body. The
backup of fluid contributes to other serious ailments
including increased susceptibility to infections and var-
ious breathing problems [20].
Alleles associated with cystic fibrosis may confer cer-
tain benefits via overdominance (i.e., heterozygotes have
higher fitness) or epistatic effects however. Data shows
that individuals in families with members identified as
suffering from CF have more offspring than individuals
from control families [21]. Even though the offspring
from CF family members experienced higher mortality
rates than the offspring of the non-CF family indivi-
duals, CF family individuals still out-reproduced non-CF
family individuals by roughly 22% (p < 0.001)[21].
Additionally, using a mouse model, an investigation
conducted by Gabriel and colleagues [22] showed that
heterozygotes for non-functioning CFTR alleles were
resistant to cholera toxin which suggests that increased
Table 1 Antagonistically pleiotropic disease alleles
Deleterious effect (disease) Gene: variation Benefit
Increased risk of cancers: ovarian
(females), prostate (males).
AR: CAG trinucleotide
repeat lengths.
Females: increased fertility via reduced degree of pre-mature ovarian failure, reduced
risk of breast cancer. Males: increased number of viable sperm, reduced risk of
Kennedy’s Disease.
Huntington’s disease. HTT: CAG trinucleotide
repeat lengths.
Increased fertility, decreased risk of certain cancers.
Sickle cell disease. Hbb: various point
mutations.
Protection against malaria in the heterozygous state.
Beta-thalassemia. HB: various point
mutations
Protection against malaria in the heterozygous state.
Glucose-6-phosphate
dehydrogenase (G6PD) deficiency.
G6PD: various
missense mutations.
Protection against malaria.
Cystic fibrosis (CF) CFTR: missense
mutation.
Increased fertility.
Increased risk of osteoporosis in
old age.
ALOX15: A:G intronic
polymorphism.
Reduced risk of osetoporosis in youth.
These diseases are described in more detail in the text, the presence of an advantage in addition to the deleterious effects of the disease is well-supported by
detailed genetic or epidemiological information.
Table 2 Putative antagonistically pleiotropic disease alleles
Disease Gene; Variation Putative Benefit
Triosephosphate Isomerase
Deficiency
TPI Gene: point mutations. Reduction in oxidative stress.
Tay Sachs HEXA: missense mutations. Protection against tuberculosis.
Hemachromatosis HFE Gene: many point mutation. Better iron absorption, increased resistance to typhoid fever and
tuberculosis
Phenylketonuria PKU: missense mutation. Lower probability of miscarriage
Leukemia PTNP11: various expression level
mutations.
Lower probability of hepatocellular carcinoma
Schizophrenia Chromosomal regions 6p22-p24 and
11q21-22.
Higher relative fertility (in unaffected relatives).
Cancer TNFRSF11B Gene; Various Polymorphisms Increased Bone Density in Females
These diseases have been proposed to have antagonistic pleiotropic effects in their etiology, but the evidence is suggestive and preliminary.
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CF. These mouse results were similar to results obtained
from human tissue cultures [23], however that study did
not explicitly demonstrate a fitness benefit to CF hetero-
zygotes in humans. Finally, an advantage arising from
decreased levels of sialic acid on cell membrane surfaces
in CF heterozygotes was proposed [24]. This decrease
could potentially provide increased resistance to influ-
enza and other myxo- and paramyxoviruses, although as
above, cell tissue culture data instead of direct compari-
sons of fitness differences between CF heterozygotes
and other individuals were used to support this hypoth-
esis [24].
The allele with the deleted CFTR codon therefore
seems to exhibit antagonistic pleiotropy. The deletion
leads to serious health issues in homozygotes, but indivi-
duals likely to be carrying the allele (I.E., families of CF
sufferers) appear to have more offspring and may
experience increased resistance to cholera and other
infectious diseases.
Sickle Cell Anemia and malaria resistance
Sickle cell disease is an autosomal recessive hemoglobi-
nopathy commonly found in individuals endemic to tro-
pical and Mediterranean regions, especially Africa [25].
Sickle cell disease is attributed to a single missense
p o i n tm u t a t i o ni nt h eH e m o g l o b i n( H b )g e n e ,t e r m e d
the Hb-S allele. The mutation leads to the replacement
of glutamine by valine at position 6 and to the develop-
ment of the characteristic abnormal sickle shaped ery-
throcytes that are associated with sickle cell anemia.
The sickle shape compromises the elasticity of the red
blood cell and causes these cells to obstruct blood flow
through narrow vessels, resulting in ischemia and other
serious problems. Although life-expectancy of indivi-
duals with the homozygous Hb-S genotype has
increased in recent years in developed nations (median
lifespan of 42-48 in the US) [26], for most of human
history (and even now in undeveloped nations) homozy-
gous individuals had very short expected life expectan-
cies (I.E., high juvenile mortality). In contrast,
individuals who are heterozygous for the Hb-S allele do
not present with full symptoms and suffer minimal
hemoglobinopathies.
The Hb-S allele provides an advantage in individuals
heterozygous for the Hb-S allele via increased resistance
to malaria, most notably during the ages of 2 to 16
months [27]. The presence of such a benefit early in life
is thought to account for the relatively higher frequency
of the sickle cell allele in geographic regions that experi-
ence high rates of malaria. Malaria is estimated to infect
approximately 400 million individuals and kill over one
million each year [28]. Although the high rate of malaria
is a relatively recent phenomenon, it has been a major
health factor for a large proportion of humanity for over
500 generations and therefore has had sufficient time to
change the frequencies of alleles associated with resis-
tance [28].
T h eH b - Sa l l e l ei sp e r h a p st h eb e s tk n o w na n dm o s t
widely used example of antagonistic pleiotropy in dis-
cussions of the topic in human disease due to the clear
deleterious effect in homozygotes combined with a clear
advantage in heterozygotes. In contrast to the previous
examples the advantages and disadvantages of this allele
are not experienced by the same individuals, but the
overall selective forces acting on the allele remain very
similar. Over mankind’s evolutionary history (and in the
present) selection both favors and acts against the Hb-S
allele simultaneously, resulting in an equilibrium at a
frequency much higher than that expected for a purely
deleterious allele.
Beta-Thalassemia and malaria resistance
Another example of antagonistic pleiotropy in a hemo-
globinopathy is the blood disorder Beta-Thalassemia
which is caused by a mutation in the beta chains of
hemoglobin [29]. Beta-Thalassemia is an autosomal,
incompletely recessive, muta t i o ni nw h i c hi n d i v i d u a l s
that are homozygous for the mutation often present
with full disease symptoms (known as Beta-Thalasse-
mia Major). Beta-Thalassemia Major symptoms include
anemia, some heart/vascular problems in adults, and
infants and newborns that are often underweight and
smaller in size than average children (experiencing the
condition termed «failure to thrive») [29]. Although
heterozygotes for the mutation often present with mild
symptoms of this disorders, they seem to suffer no dif-
ference in life expectancy relative to the general popu-
lation [30].
A study reported that the possession of the Beta-Tha-
lassemia mutation is associated with increased resistance
to malaria and that the basis for malarial protection may
be due to early childhood exposure to P. vivax resulting
in resistance to Plasmodium falciparum [31]. The pro-
tection from malaria increases the relative fitness of
these individuals greatly and is thought to account for
the relatively higher frequency of the Beta-Thalassemia
mutation in geographic regions that experience high
rates of malaria.
The Beta-Thalassemia anemia variant of hemoglobin B
mirrors the case of sickle cell anemia described above
due to the clear advantage for heterozygotes and the
clear deleterious effects in homozygotes. Interestingly,
while the sickle cell and malaria example is more widely
known and taught in biology courses, the argument for
the role of malaria in the maintenance of the Beta-Tha-
lassemia mutation via an overdominance based antago-
nistic pleiotropy mechanism predates it [31,32].
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malaria resistance
Glucose-6-Phosphate Dehydrogenase (G6PD) deficiency
is a genetic disorder that often results in hemolytic ane-
mia because G6PD is essential for the prevention of
hemolysis due to reactive oxygen species accumulating
in red blood cells during regular cellular metabolism
and from exposure to certain environmental stimuli. A
number of observed mutations to the G6PD gene cause
a truncated dehydrogenase enzyme that is severely com-
promised in function and with an estimated 400 million
affected individuals this disorder is one of the most
common among enzyme deficiencies [33]. Homozygous
(females) and hemizygous (males) individuals manifest
the effects of the recessive mutation which often results
in fetal mortality and, later in life, causes hemolytic ane-
mia if red blood cell production cannot be increased
enough to offset the rate of destruction from hemolysis.
Current studies show that the life expectancy of affected
individuals can be normal with adequate and frequent
treatment [33,34], although this treatment is not avail-
able in much of the world and was not available
throughout most of medical history.
As is the case for the hemoglobinopathies described
above, G6PD deficiency is associated with protection
from malaria. Various alleles that cause G6PD deficiency
have been associated with improved resistance to
malaria, especially to the most life-threatening cerebral
malaria, in hemizygous males and heterozygous females
[35,36].
Although they cause hemolytic anemia, the resistance
to such a widespread and serious disease conferred by
G6PD mutations may cause the net fitness effect of
these alleles to be comparable to wildtype fully func-
tional G6PD alleles. The high prevalence and serious
health consequences of malaria infection may explain
the extremely high number of cases of G6PD estimated
to exist.
ALOX15 gene and Bone Mineral Density
Osteoporosis is a condition in which the bones weaken,
making sufferers more prone to fractures in accidents
and falls, and poses a serious global health risk. For
example, in the US in 2005 there were an estimated
300,000 hip and 550,000 vertebral fractures [37] and in
a Canadian cohort study these fractures were associated
with 419% and 253% increases in mortality over the
next year respectively [38]. Clinical definition of osteo-
porosis typically includes low bone mineral density
(BMD) measurements. In a study of SNP frequencies
t h ep r e s e n c eo fag u a n i n ei n s t e a do ft h em o r ec o m m o n
adenine within intron 12 of the 12/15-lipoxygenase
(ALOX15) gene was associated with a reduced risk of
low BMD at the femoral neck in pre-menopausal
women (OR = 0.442, p = 0.007) but an increased risk in
postmenopausal women (OR = 1.727, p = 0.042) [39].
The guanine allele therefore either reduces or increases
osteoporosis risk depending on which stage of life one is
considering; if we consider the actions of ALOX15 dur-
ing different life stages to bed i f f e r e n tf u n c t i o n st h e n
this allele is a clear case of an antagonistically
pleiotropy.
Cancers and reproductive traits
Cancer is a primary cause of genetically caused mortality
worldwide, with estimates of up to 569,490 deaths in
2010 in the US alone [40]. A number of allelic variants
for certain genes have been discovered in which the
genotypes of individuals seem to correlate with risk of
developing cancer [41]. One of these genes is the andro-
gen receptor (AR) gene. The AR gene contains a
repeated CAG trinucleotide sequence and the CAG
repeat length influences gene expression, which deter-
mines the density of androgen receptors in human
epithelial tissue, mainly of the reproductive system.
In females, a shorter CAG repeat length in the AR
gene is associated with ovarian cancer. Shorter repeats
of the CAG segment have been associated with an
increased expression of the AR gene in ovarian tissue
[42,43] and another study presented a Western Blot
analysis of tissue cultures as evidence that increased
expression of AR gene is associated with ovarian tumor
formation [44]. Consistent with this process, women
who inherited a shorter repeat of the CAG segment of
the androgen receptor allele presented with an earlier
age of incidence of ovarian cancer, roughly about 7.2
years earlier compared to a control group [42].
In males, a shorter CAG repeat length in the AR gene
is associated with prostate cancer. As in ovarian tissue, a
shorter CAG repeat length is associated with increased
expression of the AR gene in prostate tissue [45]. Higher
density of AR in prostate tissue seems to amplify andro-
gen activity, which is expected to increase cell prolifera-
tion and prostate tissue growth rates [46]. Increased cell
proliferation, via hormonal stimulation for example, is
associated with an increase in frequency and malignancy
of prostate cancer [43,47]. Consistent with this process,
Ingles and colleagues reported that males with a shorter
repeat length experienced a two-fold increase in prostate
cancer risk [46]. Similarly, another investigation reported
an association between shorter CAG repeats and pros-
tate cancer in 587 prostate cancer patients and 588 con-
trol individuals and that the association was driven by
the most severe cases [48].
In contrast, shorter repeat CAG lengths within the AR
gene may provide benefits to females and males.
In females, shorter repeats may increase reproductive
ability and reduced breast cancer risk. Shorter CAG
Carter and Nguyen BMC Medical Genetics 2011, 12:160
http://www.biomedcentral.com/1471-2350/12/160
Page 6 of 13repeat lengths within the AR gene are associated with a
potential increase in reproductive fitness via the link
between AR gene expression and follicular development
during the uterine cycle. Serum androgen activity is
mediated by the androgen receptor and the effects
appear additive, implying that a high density of the
receptor (such as that caused by increased expression
due to shorter repeat lengths) would amplify androgen
activity. Androgen activity is associated with follicular
growth and maturation and increases the viability of
oocytes, which increases fertility [49]. Consistent with
this process is evidence provided by Chaterjee and col-
leagues in which shorter CAG repeat lengths were asso-
ciated with a reduced degree of pre-mature ovarian
failure [50]. Shorter repeat lengths may also provide an
advantage via reduced cancer risk; in a study of women
with the BRCA1 allele, shorter CAG repeat lengths
within the AR gene were associated with reduced risk of
breast cancer [51].
In males, shorter CAG repeat lengths within the AR
gene are associated with a potential increase in repro-
ductive ability, reduced risk of Kennedy’sd i s e a s ea n d
perhaps greater sexual attractiveness. There is evidence
of an inverse relation between CAG repeat lengths in
the AR gene and the level of reproductive fitness; on
average, males with a shorter CAG repeat length pre-
sented with fewer non-viable, defective sperm [52]. The
l e v e lo fs e v e r i t ya n dt h ea s s ociated amount of defective
sperm were directly correlated to longer repeat lengths
and individuals with shorter repeats experienced
reduced rates of infertility. There is also evidence that a
shorter repeat length is associated with increased counts
of viable sperm in adolescent males [53]. Shorter repeat
lengths may provide an advantage via reduced risk of
Kennedy’s disease, a neuromuscular disease similar to
ALS that only affects males. In a study of 35 unrelated
men with Kennedy’s disease and 75 controls [54] all the
affected males had longer CAG repeat lengths. It
appears that a decreased repeat length is associated with
higher expressions of a range of male- specific traits
that may have had (or indeed, still have) roles in mate
acquisition and attraction.
Variation in the CAG repeat length within the AR
gene therefore seems to exhibit antagonistic pleiotropy
in both females and males. In females, shorter CAG
repeat lengths correlate with increased risk of ovarian
cancer, the second leading cause of gynecological cancer
deaths [55], yet shorter repeats are also associated with
increased reproductive fitness via increased viability of
oocytes and reduced pre-mature ovarian failure as well
as reduced breast cancer risk. In males, shorter CAG
repeat length is associated with decreased survivorship
(mostly in older age) due to higher risk of prostate car-
cinogenesis, but shorter repeats are associated with
increased reproductive fitness (manifested mainly in
youth) via increased viability of sperm, reduced risk of
Kennedy’s disease and perhaps increased reproductive
opportunities due to phenotypic traits that are more
attractive to females.
Other putative antagonistically pleiotropic alleles
The examples of antagonistic pleiotropy cited above
demonstrate the widespread nature of this phenomenon
in terms of physiological systems and tissues as well as
mechanisms of action. The previous examples are based
on specifically characterized genes; other possible occur-
rences of antagonistic pleiotropy in humans have been
suggested, based upon correlations and less comprehen-
sive data. Further investigation of the proposed cases of
antagonistically pleiotropic alleles below seems war-
ranted in order to round out our understanding of the
pervasiveness of this phenomenon.
R e c e n te v i d e n c es u g g e s t st h a tt h e r em a yb eal i n k
between Triose Phosphate Isomerase (TPI) deficiency, a
disease that causes a number of severe symptoms
(chronic hemolytic anemia, cardiomyopathy, susceptibil-
ity to infection and severe neurological dysfunction), but
may also confer oxidative stress resistance. TPI defi-
ciency in yeast confers a protective benefit by reducing
oxidative stress during cellular metabolism [56], which
suggests that humans who are heterozygous for the
mutant TPI allele may also experience this benefit.
However, more definitive evidence involving vertebrate
models, if not human models, are necessary to further
validate this hypothesis.
Tay Sachs disease, a severe neurodegenrative disease
due to a number of different mutations described in the
HEXA gene which encodes the alpha-subunit of the
lysosomal enzyme beta-N-acetylhexosaminidase, has
been proposed to owe its surprisingly high frequency to
the benefit provided by protection from tuberculosis
during the historical process of urbanization [57,58].
Hemochromatosis, a well-known blood disease, has a
very clear genetic basis in its manifestation and progres-
sion [59] and is often the result of many different poten-
tial mutations to different genes with the most common
mutation being the C282Y mutation of the HFE gene.
Evidence suggests that individuals heterozygous for the
C282Y mutation in the HFE gene may experience bene-
fit due to more efficient dietary iron absorption and via
increased resistance to typhoid fever and tuberculosis,
diseases that became more prevalent with the rise of
urbanization [59].
Phenylketonuria (PKU) may also display evidence of
selection by antagonistic pleiotropy. Woolf [60] pre-
sented data which suggests that heterozygote females
may experience a lower chance of mold infection
induced miscarriages; potentially an important
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and storage. Although the PKU causing allele is likely to
be purely deleterious today, its historical heterozygote
advantage may account for its current prevalence. The
sample of PKU individuals referenced in that study was
small and included only individuals in Ireland and Scot-
land where mold problems have have been more severe
than elsewhere, alternative explanations may be neces-
sary to explain the global distribution of PKU.
Another putative example involves hepatocellular car-
cinoma (HCC), a well-known cancer, and the PTNP11
gene. The wild type allele for PTNP11 is proto-onco-
genic and produces the shp2 protein. In its wild-type
form, PTNP11 aids in the prevention of HCC but may
also contribute to the manifestation of leukemia. Cha-
peau and colleagues showed that mice and human Leu-
kemia cases are associated with a mutation that leads to
t h eo v e r e x p r e s s i o no ft h eP T N P 1 1g e n e[ 6 1 ] .T h e y
investigated mouse models with the PTNP11 allele
knocked out to simulate under-expression of the gene
and the mice were less prone to develop leukemia, but
many developed HCC [61]. This data suggests an antag-
onistic relationship between the levels of PTNP11
expression and the development of leukemia and HCC;
further studies must be performed to properly ascertain
this same relationship in humans.
Even psychological disorders may be subject to selec-
tion of antagonistically pleiotropic alleles. Schizophrenia
is believed to have a heritable component with alleles
implicated for genetic susceptibility reported to be
located in chromosomal regions 6p24-p22 [62] and per-
haps 11q21-22[63]. Other studies have shown that
although schizophrenic individuals themselves have
reduced reproductive success, their unaffected relatives
often have higher relative fertility [64], indicating a
potential advantage conferred by alleles associated with
schizophrenia when those are present as single copies or
in different genetic backgrounds (i.e., different epistatic
interactions).
Osteoprogesterin (OPG) is a cytokine receptor protein
that has a role in malignant tumor progression and
modulation of bone density. OPG is encoded by the
tumor necrosis factor receptor superfamily member 11B
(TNFRSF11B) gene [65]. Overexpression of the
TNFRESF11B gene has been associated with several
epithelial cancers [66] and another study has suggested
that OPG does, in fact, have a modulatory role in tumor
angiogenesis [67]. Furthermore, Ito et al [66] have sug-
gest that overexpression is positively correlated with the
severity of the associated epithelial cancer (i.e., malig-
nancy increases with the concentration of OPG in the
blood). A high level of OPG has also been shown to
decrease the likelihood of bone disease; Samuelson and
colleagues presented a human clinical study in which a
higher than normal level of OPG was associated with
stronger bones in both men and women [68]. OPG may
act as a promoter of osteoblast activity by reducing the
number of activated osteoclasts in the blood. Human
clinical studies have shown that there is an association
in increased Bone Mineral Density (BMD) in individuals
who have higher circulating levels of OPG in their
blood plasma. Such costs and benefits associated with
the TNFRSF11B gene would be an example of antago-
nistic pleiotropy, but further evidence, including the
identification of the specific genetic polymorphism
responsible, is needed to support this hypothesis.
For these less characterized cases of antagonistic
pleiotropy, and other cases not identified yet, the genetic
mechanism providing the advantage may be straightfor-
ward or more complex. The most straightforward
mechanism is overdominance (heterozygote advantage),
but incomplete penetrance of the deleterious aspect of
the alleles or epistatic interactions that differ in different
genetic backgrounds may also be important for the full
fitness ramifications of disease alleles. The latter two
mechanisms are more subtle and difficult to recognize
or demonstrate statistically and this may contribute to
the unresolved nature of the examples described in this
section.
Given the number of diseases caused by antagonisti-
cally pleiotropic alleles that have been identified to date
and the potential complexity of the mechanisms provid-
ing the benefits, many more genetic disorders may exist
that have yet to be identified as antagonistically
pleiotropic.
Discussion
We have presented a number of examples where antag-
onistic pleiotropy has been demonstrated (Table 1) or
proposed (Table 2) for disease causing alleles. We feel
that antagonistic pleiotropy may provide a potential
explanation for the sustained prevalence of many dis-
ease-associated alleles in the human population and may
be a widespread phenomenon. Because individuals who
possess these alleles may have an equal or comparable
relative fitness despite their allele’s deleterious effects
(or the increased risk of experiencing deleterious effects)
we predict that pathology-associated alleles will continue
to be present in successive generations despite their
apparent maladaptive nature.
Although some of the studies cited predict an increase
in the frequency of these pleiotropic alleles (e.g.,[15]),
whether or not the frequencies of these alleles will
increase in successive generations is influenced by chan-
ging environmental, medical and social conditions which
alter the negative and positive aspects of genetic fitness
differences. For example, chelation treatments for Beta-
thalassemia have shown great benefit, changing the life
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to as high as 55 years of age [69]. Another example is
seen in CF patients where improved medical care in
modern times has increased life expectancy of CF indivi-
duals from infancy to mid-reproductive age. Even
though mortality is still usually experienced before the
onset of post-reproductive age, this increase in life-
expectancy can have a rather large impact on the repro-
ductive fitness of CF individuals. With the deleterious
effects on mortality reduced by modern medicine and
the benefits intact these disease alleles would now have
a higher net advantage and be expected to rise in fre-
quency more than would have been possible prior to
modern medicinal techniques.
On the other hand, since many of the benefits we
have discussed involve resistance to diseases that mod-
ern medicine will render rarer or more treatable, the
benefits may also be reduced and the net change in the
fitness provided by these antagonistically pleiotropic
alleles is less clear. In fact, because many of the benefits
we identified involve resistance to pathogens that are
now treated effectively, we may expect these advanta-
geous effects to be reduced and natural selection to be
more effective at reducing the frequencies of these
alleles in the future. This evolutionary process is typi-
cally very slow however, and even if the alleles become
purely deleterious, the elimination of these alleles would
take a long time.
One readily noticeable feature of the examples of
antagonistic pleiotropy we identified is the overabun-
dance of advantageous effects involving malaria; we
believe that such bias toward examples involving malaria
is due primarily to two major reasons. First, there is a
bias in favor of the search for, and recognition of,
malaria resistance benefits due to the high profile of
Beta-Thalassemia and Sickle-Cell disease which are both
such well-known examples of over-dominance that they
are often taught in the introductory biology curriculum
that medical researchers experience. Such previous
exposure pre-disposes epidemiological researchers to
consider malaria foremost when investigating explana-
tions for the high frequency of disease alleles. For exam-
ple, a recent epidemiological study was able to generate
a highly detailed map of the distribution of malaria
cases worldwide [28]. In accordance with expectations,
the highest prevalence of malaria incidences occurred in
Mediterranean and African regions, displaying a 58%
prevalence rate in 2010. This is an increase since 2002
from a prevalence rate of 56.9%. We, therefore, expect
the highest frequencies of malaria resistance mutations
to be found in these regions and studies such as this
one indicate the level of attention paid to this disorder.
Second, the ease with which heterozygous advantage
can be demonstrated with these diseases can also be a
contributing factor. Malaria is mainly confined to Medi-
terranean and tropical regions of the world and such a
clear geographical distribution allows for a relatively
straightforward comparison of allele frequencies in
regions likely and unlikely to benefit from malaria pro-
tection. Malaria is also a very common and serious dis-
order overall, leading public health agencies to collect
detailed data and provide funding for research related to
understanding this disease.
Recognition of the advantageous effects of other dis-
ease alleles may be harder to demonstrate experimen-
tally if the advantage provided by the allele does not
have a clear and qualitative effect (e.g., if the advantage
is only a reduced risk of a disorder rather than a com-
plete elimination of a condition). Such advantageous
effects may not be recognized except in studies with
large sample sizes in which many aspects of the health
of the subjects are recorded. The recent rise of SNP-
based association studies may lead to many more dis-
coveries, but only if researchers are measuring a wide
range of fitness components. In the ALOX15/BMD
example described above [39], the pleiotropy of the
identified allele was only recognized because the effects
both involved the measured trait. The increased repro-
duction associated with the Huntington’s disease allele
was only demonstrable by measuring the number of off-
spring born to sufferers [15].
For these reasons we recommend that many more
variables be measured when conducting studies of asso-
ciations between alleles and medical conditions that are
typically included in published analyses. Life history
variables such as total reproduction or age at first repro-
duction are directly related to fitness and advantageous
genetic effects may be made apparent if these values are
recorded. We also suggest that additional health relevant
statistics such as blood pressure, cholesterol or BMI be
measured and included in studies of associations
between alleles and medical conditions as they may
reveal otherwise overlooked advantageous aspects of
allelic differences. Measurement of additional variables
c a r r i e st h er i s ko ff a l s e - p o s itives, but follow up studies
can be used to minimize that risk whereas failure to
record data leads to missed effects that would not be
discovered later.
Antagonistic pleiotropy may also have been over-
looked because the benefits of these alleles may not be
large enough to be readily noticeable when compared to
the detrimental effects. A brief mathematical illustration
using standard techniques from population genetics (i.e.,
Hardy-Weinberg style formulations of equilibrium allele
frequencies) demonstrates that even minor benefits can
result in moderate equilibrium allele frequencies in the
case of overdominance (heterozygote advantage). First,
define two alleles, «A» and «a», as the wildtype and the
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genotypes of w(AA) = 1, w(Aa) = 1+Sadv,w ( a a )=1 - S del.
For example, a value of Sadv = 0.1 would indicate a 10%
higher fitness for heterozygotes whereas a value of Sdel
= 0.2 indicates a 20% lower fitness for homozygous for
the «a» allele - a value of Sdel =1w o u l db ea na l l e l e
that is completely lethal in homozygotes. Using the
terms above, and assuming that reproductive decisions
are not biased by assortative mating or other factors
aside from selection on the alleles, we can derive the fol-
lowing formulae for the equilibrium frequencies of the
«a» allele and «aa» genotype:
f(a) =S adv/(2Sadv +S del), f(aa) =S adv
2/(2Sadv +S del)2
Figures 1 and 2 show predicted equilibrium frequen-
cies of the homozygous deleterious genotype for a wide
range of realistic parameters. It may seem unlikely that
situations in which the advantages plotted in Figures 1
and 2 are not well known, but selective advantages as
high as the 25% shown may be unrecognized - the 39%
advantage reported for individuals with the Huntington’s
allele relative to their unaffected siblings [15] was not
obvious prior to study [59]. Even in cases in which the
heterozygous advantage is minimal (approximately 1%)
and the allele is lethal in the homozygous state, natural
selection is expected to act to maintain the alleles and
result in long-term frequencies of afflicted individuals
higher than 1 in 10,000 instead of acting to remove
them from the population. This conceptual example
illustrates the potential for selection to maintain alleles
at medically relevant frequencies even while the benefits
conferred may be subtle enough as to be largely unno-
ticed in a clinical setting.
Selective benefit is not required for the observed pre-
sence of deleterious alleles in a population; purely dele-
terious alleles that confer no advantages persist in
populations over time due to recurrent mutations coun-
tering the process of elimination by selection. Similar
calculations to those above result in predicted equili-
brium frequencies much smaller however; ranging from
genotypic frequencies of approximately 0.0001% for
lethal alleles up to 0.01% for alleles that incur an essen-
tially unnoticeable 1% fitness reduction.
These calculations lead us to predict that from the
wide array of known genetic disorders, it is the ones
with the highest frequencies that we predict to be most
likely to have antagonistically pleiotropic benefits. The
process of antagonistic pleiotropy may therefore be
highly relevant for understanding the genetic disorders
most commonly experienced (i.e., those that tend to
result in the highest burden to society). For more com-
plex cases of antagonistic pleiotropy which do not fit
the overdominant model examined here, we would gen-
erally expect the beneficial aspects of each allele’s
actions to be comparable to the deleterious effect in
order to maintain the allele in the long term - this leads
us to predict that we would see antagonistically pleiotro-
pic effects more often for serious medical conditions in
which the deleterious effects are more severe.
For these reasons, rather than being a process that is
involved in the etiology of a random subset of all
genetic disorders, we expect to see antagonistic pleio-
tropy overrepresented in the diseases that are the most
common and have the most severe consequences.
Finally, if antagonistic pleiotropy is indeed as wide-
spread as our reviewed findings and mathematical
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pleiotropic allele. Equilibrium frequencies for heterozygous
advantages, Sadv, of 0.1%, 1%, 5% and 25% are shown for a range of
homozygous deleterious effects, Sdel, ranging from 0% (no
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nomenon presents two major implications for the
research and treatment of human genetic disease.
First, identification of pleiotropic alleles that confer
disease resistance or other benefits and elucidation of
their mechanisms of action may aid medical and patho-
physiological research. For example, in the case of Tay
Sachs, if the hypothesized anti-tuberculosis benefit pro-
vided by this allele is demonstrated then identification
of the exact cause of this benefit may be useful for the
development of novel treatments for tuberculosis - a
serious need now that more and more drug resistant
strains have evolved. Advances in understanding phy-
siology may also arise from identification of benefits
unrelated to disease resistance; a full elucidation of the
genetic aspects that contribute to the process by which
Huntington’s sufferers produce more offspring may
prove useful for infertility treatment.
Second, if antagonistically pleiotropic effects are per-
vasive then this suggests that we use caution when we
design genetically-based treatments for diseases. One
currently proposed method for treating or preventing
cancer is silencing gene expression via interference RNA
[70,71]; if such mechanisms completely silence the
expression of an antagonistically pleiotropic allele this
w o u l dl e a dt oar e d u c t i o nn ot only in the deleterious
effect but also in any beneficial effects. By eliminating a
problem we may also eliminate a benefit. For example,
silencing an allele that increases the density of AR
receptors may reduce cancer risk, but may also cause
physiological changes that result in the patient’s pheno-
typic traits becoming less attractive to members of the
opposite sex. Especially since the main use of the identi-
fication of genetic gene-disease associations in the future
will be to decide on prophylactic treatment, a full
understanding of the risks and the benefits of under-
going such gene-targeted treatment is essential to ethical
patient care. In cases in which a benefit is unknown (but
we argue, may well exist), the unknown consequences of
turning off potentially pleiotropic alleles implies that a
different overall approach should be considered to avoid
potential unwanted or disastrous side-effects. Rather
than just focusing on a culprit disease allele and silen-
cing it, selectively inhibiting the allele’s deleterious path-
way while allowing the beneficial pathway to persist
becomes a more responsible, albeit more difficult,
course of action.
Conclusion
We have identified a number of empirical examples
where antagonistic pleiotropy has been demonstrated
and more where such pleiotropy is likely. A population
genetic model suggests that alleles with extremely minor
fitness advantages may maintain otherwise deleterious
alleles at medically relevant frequencies. Based on the
availability of this information despite no concerted
research effort to gather it and the mathematical argu-
ment we feel that such antagonistic pleiotropy may be a
widespread phenomenon. If such pleiotropy is wide-
spread this opens avenues for the identification of novel
physiological pathways by the study of the pleiotropic
effects of disease alleles and suggests that caution be
taken when designing genetic therapies to eliminate the
effects of genes lest their beneficial effects be removed
as well.
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